JP2006512320A - Nadh/nadphを含む組成物 - Google Patents
Nadh/nadphを含む組成物 Download PDFInfo
- Publication number
- JP2006512320A JP2006512320A JP2004552258A JP2004552258A JP2006512320A JP 2006512320 A JP2006512320 A JP 2006512320A JP 2004552258 A JP2004552258 A JP 2004552258A JP 2004552258 A JP2004552258 A JP 2004552258A JP 2006512320 A JP2006512320 A JP 2006512320A
- Authority
- JP
- Japan
- Prior art keywords
- antioxidant
- composition according
- composition
- nadh
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 75
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title claims description 43
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 title claims description 37
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 title claims 2
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 107
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 89
- 238000000034 method Methods 0.000 claims abstract description 17
- 235000006708 antioxidants Nutrition 0.000 claims description 104
- 239000000126 substance Substances 0.000 claims description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 31
- 239000001301 oxygen Substances 0.000 claims description 31
- 229910052760 oxygen Inorganic materials 0.000 claims description 31
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- 230000014759 maintenance of location Effects 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 13
- YPZRHBJKEMOYQH-UYBVJOGSSA-N FADH2 Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-N 0.000 claims description 12
- 229930003802 tocotrienol Natural products 0.000 claims description 11
- 239000011731 tocotrienol Substances 0.000 claims description 11
- 235000019148 tocotrienols Nutrition 0.000 claims description 11
- 229930002875 chlorophyll Natural products 0.000 claims description 10
- 235000019804 chlorophyll Nutrition 0.000 claims description 10
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical group C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 10
- 239000011261 inert gas Substances 0.000 claims description 10
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 9
- YTNIXZGTHTVJBW-SCRDCRAPSA-N FMNH2 Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2NC2=C1NC(=O)NC2=O YTNIXZGTHTVJBW-SCRDCRAPSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 206010016256 fatigue Diseases 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 206010024264 Lethargy Diseases 0.000 claims description 3
- 238000001784 detoxification Methods 0.000 claims description 3
- 235000019136 lipoic acid Nutrition 0.000 claims description 3
- 230000010627 oxidative phosphorylation Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229960002663 thioctic acid Drugs 0.000 claims description 3
- 108010074122 Ferredoxins Proteins 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 230000036541 health Effects 0.000 abstract description 12
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000003019 stabilising effect Effects 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 229910002012 Aerosil® Inorganic materials 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000010525 oxidative degradation reaction Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 229930003799 tocopherol Natural products 0.000 description 5
- 239000011732 tocopherol Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 108091006149 Electron carriers Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940084569 chlorophyll 20 mg Drugs 0.000 description 2
- 229940021773 chlorophyll 60 mg Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003050 macronutrient Effects 0.000 description 2
- 235000021073 macronutrients Nutrition 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940068778 tocotrienols Drugs 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 208000030663 Libido disease Diseases 0.000 description 1
- 101800000628 PDH precursor-related peptide Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 108010081996 Photosystem I Protein Complex Proteins 0.000 description 1
- 108010060806 Photosystem II Protein Complex Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000036782 biological activation Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 1
- QXWRYZIMSXOOPY-SKHCYZARSA-M chlorophyll d Chemical compound C1([C@H](C2=O)C(=O)OC)=C(N3[Mg]N45)C2=C(C)\C3=C\C(=N2)C(CC)=C(C)\C2=C\C4=C(C=O)C(C)=C5\C=C/2[C@@H](C)[C@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C1=N\2 QXWRYZIMSXOOPY-SKHCYZARSA-M 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000007871 hydride transfer reaction Methods 0.000 description 1
- 150000002483 hydrogen compounds Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- DGNIJJSSARBJSH-NLJAFYFLSA-L magnesium (E)-3-[(3R)-16-ethenyl-11-ethyl-3-methoxycarbonyl-12,17,21,26-tetramethyl-4-oxo-7,24-diaza-23,25-diazanidahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1(22),2(6),5(26),7,9,11,13,15(24),16,18,20-undecaen-22-yl]prop-2-enoic acid Chemical compound [Mg++].CCc1c(C)c2cc3nc(cc4[n-]c(c(\C=C\C(O)=O)c4C)c4[C@@H](C(=O)OC)C(=O)c5c(C)c(cc1[n-]2)nc45)c(C)c3C=C DGNIJJSSARBJSH-NLJAFYFLSA-L 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- JOUIQRNQJGXQDC-ZYUZMQFOSA-L nicotinate D-ribonucleotide(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1[N+]1=CC=CC(C([O-])=O)=C1 JOUIQRNQJGXQDC-ZYUZMQFOSA-L 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本実施例では、NADH(−320mV)を抗酸化剤Aとして使用した。酸素隔離性油性物または強力な抗酸化剤によるNADHの保護作用を具体化するために、NADHと高トコトリエノールのコムギ種子油(以下油性物と呼ぶ)との混合物およびクロロフィルを、−660mVの酸化還元電位を有する抗酸化剤Bとして、補助物質として不活性のエアロジルを使用して調製した。
配合物1番: NADH 20mg
油性物 20mg
エアロジル 20mg
配合物2番: NADH 20mg
油性物 60mg
エアロジル 30mg
配合物3番: NADH 20mg
クロロフィル 20mg
エアロジル 20mg
配合物4番: NADH 20mg
クロロフィル 80mg
エアロジル 20mg
配合物5番: NADH 20mg
油性物 20mg
クロロフィル 20mg
エアロジル 20mg
配合物6番: NADH 20mg
油性物 20mg
クロロフィル 60mg
エアロジル 20mg
配合物7番: NADH 20mg
エアロジル 20mg
配合物8番: NADH 20mg
油性物 20mg
クロロフィル 60mg
エアロジル 20mg
配合物1〜7番は、不活性ガスとして窒素の下で混合し、続いて硬質ゲルカプセル中に充填し、ポリプロピレン容器に詰めた。
8種のテスト標本の全てを25℃及び相対湿度60%の長期条件下で6カ月間貯蔵し、1カ月間隔で化学的分析調査を行った。分析はNADHからNAD+へのまたは他の化合物への酸化分解を測定することを目的とした。
HPLC: アジレント(Agilent)1100シリーズ;
四進ポンプ、自動採取器、カラム温度調整、および
可変波長検出器(VWD)または蛍光検出器(FLD)
を各々付属
分離カラム: リクロスファー(LiChrospher)(商標)100
RP−18(5μm)250×4mm(含、ガードカラム
4×4mm)
カラム温度調整: 25℃
溶離液: 900mlのH2O、60mlのCH3CN、23mlの
THF、1mlのリン酸および1.2gの
オクタンスルホン酸ナトリウム(NaOSS)
流量: 1.5ml/分
検出: VWD:260nm
FLD:励起:290nm、発光:395nm
保持時間: NADH:1.04分
NAD+:1.34分
標準化
商業的に入手可能なNADH(ファネンシュミット社(Pfannenschmidt GmbH)およびNAD+(シグマアルドリッチ社)のそれぞれのストック溶液の連続希釈物を利用して、2つの物質の直線検量線が、1〜50mg/l(FLD)および10〜200mg/l(VWD)の範囲でそれぞれ決定できた。
カプセルの内容物を、螺子栓付瓶に入れ、50mlの蒸留水を補給し、1分激しく攪拌する。
サンプル1番〜8番のNADHの含有量の評価を表および図面に表示する。
Claims (16)
- −180mV未満の酸化還元電位を有する少なくとも1種の分離された健康増進性抗酸化剤A、および前記抗酸化剤Aを安定化し、前記抗酸化剤Aの標準酸化還元電位未満範囲にある酸化還元電位を有する少なくとも1種の分離された抗酸化剤Bを含むことを特徴とする組成物。
- 前記抗酸化剤Aが、NADH、NADPH、還元型αリポ酸、還元型グルタチオン、FADH2、FMNH2、FADH、およびFMNHからなる群から選択されることを特徴とする、請求項1に記載の組成物。
- 前記抗酸化剤Bが、クロロフィルおよび/または還元型フェレドキシンであることを特徴とする、請求項1または2に記載の組成物。
- 酸素隔離物質をさらに含むことを特徴とする、請求項1から3のいずれか一項に記載の組成物。
- 前記酸素隔離物質が、含油物質であることを特徴とする、請求項4に記載の組成物。
- 前記酸素隔離物質が、少なくとも1種の別の抗酸化剤Cを含む含油物質であることを特徴とする、請求項5に記載の組成物。
- 前記酸素隔離物質が、前記抗酸化剤CとしてビタミンE、特にトコトリエノールを含むことを特徴とする、請求項6に記載の組成物。
- 前記抗酸化剤Aおよび抗酸化剤Bが、10:1から1:10、好ましくは3:1から1:3の間の比率で供給されることを特徴とする、請求項1から7のいずれか一項に記載の組成物。
- 1種または数種の補助剤をさらに含むことを特徴とする、請求項1から8のいずれか一項に記載の組成物。
- 請求項1から9のいずれか一項に記載の組成物の栄養補助剤としての使用。
- 請求項1から9のいずれか一項に記載の組成物の薬物としての使用。
- 酸化的リン酸化を促進する薬剤、認知能力、知的能力および運動能力を促進する薬剤、肝臓の合成および解毒作用を促進する薬剤、疲労、無気力、性欲障害および性交能力障害、うつ病、学習および集中力の低下を治療する薬剤からなる群から選択される薬剤を調製するための、請求項1から9のいずれか一項に記載の組成物の使用。
- 錠剤、液剤、カプセル剤、コーティング錠、シロップ剤、ローション剤、クリーム剤、散剤の形態で提供されることを特徴とする、請求項1から9のいずれか一項に記載の組成物。
- 前記抗酸化剤A、前記抗酸化剤B、ならびに任意選択で酸素隔離物質を互いに混合し、前記組成物を、錠剤、液剤、カプセル剤、コーティング錠、シロップ剤、ローション剤、クリーム剤または散剤に任意選択で加工することを特徴とする、請求項1から9のいずれか一項に記載の組成物を調製する方法。
- 前記抗酸化剤A、前記抗酸化剤B、および任意選択で前記酸素隔離物質を不活性ガスの下で混合することを特徴とする、請求項14に記載の方法。
- 前記組成物を不活性ガスの下で加工することを特徴とする、請求項14または15に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0173402A AT502435B1 (de) | 2002-11-19 | 2002-11-19 | Pharmazeutische zusammensetzung umfassend ein wasserstoffübertragendes coenzym und chlorophyll |
PCT/AT2003/000346 WO2004045626A1 (de) | 2002-11-19 | 2003-11-19 | Zusammensetzung umfassend nadh/nadph |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011039874A Division JP2011144186A (ja) | 2002-11-19 | 2011-02-25 | Nadh/nadphを含む組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006512320A true JP2006512320A (ja) | 2006-04-13 |
Family
ID=32315086
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004552258A Pending JP2006512320A (ja) | 2002-11-19 | 2003-11-19 | Nadh/nadphを含む組成物 |
JP2011039874A Pending JP2011144186A (ja) | 2002-11-19 | 2011-02-25 | Nadh/nadphを含む組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011039874A Pending JP2011144186A (ja) | 2002-11-19 | 2011-02-25 | Nadh/nadphを含む組成物 |
Country Status (18)
Country | Link |
---|---|
US (1) | US7255813B2 (ja) |
EP (1) | EP1562613B1 (ja) |
JP (2) | JP2006512320A (ja) |
CN (1) | CN1713916A (ja) |
AT (2) | AT502435B1 (ja) |
AU (1) | AU2003287740A1 (ja) |
CA (1) | CA2503860C (ja) |
DE (1) | DE50309383D1 (ja) |
DK (1) | DK1562613T3 (ja) |
ES (1) | ES2302957T3 (ja) |
HR (1) | HRP20050573B1 (ja) |
NO (1) | NO333911B1 (ja) |
PL (1) | PL214006B1 (ja) |
PT (1) | PT1562613E (ja) |
RS (1) | RS51606B (ja) |
RU (1) | RU2338540C2 (ja) |
SI (1) | SI1562613T1 (ja) |
WO (1) | WO2004045626A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011144186A (ja) * | 2002-11-19 | 2011-07-28 | Nutropia Ernaehrungsmedizinische Forschungs Gmbh | Nadh/nadphを含む組成物 |
JP2012161293A (ja) * | 2011-02-08 | 2012-08-30 | Shin Nihon Iyaku Corp | 酸化誘導性が向上した緑茶抽出液及びこれを含有してなる食品、飲料、洗浄剤及び抗菌剤 |
JP2015040204A (ja) * | 2013-08-23 | 2015-03-02 | 京都府公立大学法人 | 運動機能性向上剤 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104306390A (zh) * | 2014-10-23 | 2015-01-28 | 苏州人本药业有限公司 | 还原型辅酶ⅱ的用途 |
JP6129395B1 (ja) * | 2016-10-29 | 2017-05-17 | 誠一 荒木 | ミトコンドリア活性化に起因した血管内皮細胞保護回復用還元型ビタミンb2製剤 |
WO2018148930A1 (zh) * | 2017-02-17 | 2018-08-23 | 纯菁生物科技(美国)有限公司 | Nadh或者fadh2在癌症病人的营养干预上的应用 |
CN107213159B (zh) * | 2017-06-05 | 2020-06-23 | 苏州人本药业有限公司 | Nadph在制备抗焦虑药物中的应用 |
CN107213160B (zh) * | 2017-06-06 | 2020-07-24 | 重庆纳德福实业集团有限公司 | Nadph在拮抗药物致线粒体毒性中的应用 |
CN109432181A (zh) * | 2018-12-19 | 2019-03-08 | 泓博元生命科技(深圳)有限公司 | 缓解抑郁症的组合物及其制备方法与应用 |
CN109620863A (zh) * | 2018-12-19 | 2019-04-16 | 泓博元生命科技(深圳)有限公司 | 一种缓解抑郁症的组合物及其制备方法与应用 |
CN110339179A (zh) * | 2019-05-29 | 2019-10-18 | 泓博元生命科技(深圳)有限公司 | 含nadh或nadph的软胶囊及其制备方法和应用 |
CN112384080A (zh) * | 2019-06-04 | 2021-02-19 | 邦泰合盛生物科技(深圳)有限公司 | 辅酶膳食营养补充剂及其制备方法和应用 |
CN110237089A (zh) * | 2019-06-19 | 2019-09-17 | 泓博元生命科技(深圳)有限公司 | Nadh和/或nmn防治男性勃起功能障碍的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS614798A (ja) * | 1984-06-19 | 1986-01-10 | 東亞合成株式会社 | 高度不飽和脂肪酸組成物 |
JPH05503071A (ja) * | 1989-08-18 | 1993-05-27 | ジョン・モリス・カンパニー・インク | ケラチン組織、皮膚状態を治療し、創傷の治癒を促進させる臭気遮断及び安定化組成物 |
JPH08231404A (ja) * | 1995-01-17 | 1996-09-10 | Birkmayer Usa | 経鼻、経舌下、経直腸及び経皮投与のためのnadh及びnadph治療剤 |
JPH08512021A (ja) * | 1993-04-29 | 1996-12-17 | バークメイヤー ユー.エス.エー. | 安定性、摂取可能及び吸収性のnadh及びnadph治療組成物 |
JP2001061498A (ja) * | 1999-08-31 | 2001-03-13 | Oriental Yeast Co Ltd | 還元型補酵素溶液 |
EP1161884A1 (en) * | 2000-06-09 | 2001-12-12 | World Pharma Tech Ltd. | Proenergetic food supplement based on NADH, Octacosanol and Vitamin E |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3934369A (en) * | 1974-04-23 | 1976-01-27 | University Of Illinois Foundation | Vitro net bioxynthesis of chlorophyll and grana |
JPS59216824A (ja) * | 1983-05-24 | 1984-12-06 | Yoshiro Shimura | 健康増進剤 |
JPS60132987A (ja) * | 1983-12-22 | 1985-07-16 | Riken Vitamin Co Ltd | クロロフイル組成物 |
JPS60221749A (ja) * | 1984-04-18 | 1985-11-06 | Mitsubishi Electric Corp | 光記録媒体 |
JPS63237584A (ja) * | 1987-03-26 | 1988-10-04 | Mitsubishi Electric Corp | 光応答性スイツチ素子 |
US5760206A (en) * | 1992-12-11 | 1998-06-02 | E. I. Du Pont De Nemours And Company | Nucleotide sequence of soybean stearoyl-ACP desaturase gene |
US5777190A (en) * | 1997-05-29 | 1998-07-07 | Battelle Memorial Institute | Method of controlled reduction of nitroaromatics by enzymatic reaction with oxygen sensitive nitroreductase enzymes |
US6133227A (en) * | 1997-06-23 | 2000-10-17 | The Procter & Gamble Company | Enzymatic detergent compositions |
JPH11292737A (ja) * | 1998-02-16 | 1999-10-26 | Shiseido Co Ltd | 免疫賦活剤 |
US6124242A (en) * | 1998-06-26 | 2000-09-26 | Basf Aktiengesellschaft | Herbicidal compositions and processes based on ferrodoxin:NADP reductase inhibitors |
RU2143212C1 (ru) * | 1998-07-29 | 1999-12-27 | Общество с ограниченной ответственностью "Фитолон" | Биологически активная добавка |
AT502435B1 (de) * | 2002-11-19 | 2008-01-15 | Oekopharm Forschungs Und Entwi | Pharmazeutische zusammensetzung umfassend ein wasserstoffübertragendes coenzym und chlorophyll |
-
2002
- 2002-11-19 AT AT0173402A patent/AT502435B1/de not_active IP Right Cessation
-
2003
- 2003-11-19 AT AT03779534T patent/ATE388714T1/de active
- 2003-11-19 WO PCT/AT2003/000346 patent/WO2004045626A1/de active IP Right Grant
- 2003-11-19 CA CA2503860A patent/CA2503860C/en not_active Expired - Lifetime
- 2003-11-19 JP JP2004552258A patent/JP2006512320A/ja active Pending
- 2003-11-19 EP EP03779534A patent/EP1562613B1/de not_active Expired - Lifetime
- 2003-11-19 PT PT03779534T patent/PT1562613E/pt unknown
- 2003-11-19 AU AU2003287740A patent/AU2003287740A1/en not_active Abandoned
- 2003-11-19 RU RU2005119190/15A patent/RU2338540C2/ru active IP Right Revival
- 2003-11-19 DK DK03779534T patent/DK1562613T3/da active
- 2003-11-19 ES ES03779534T patent/ES2302957T3/es not_active Expired - Lifetime
- 2003-11-19 DE DE50309383T patent/DE50309383D1/de not_active Expired - Lifetime
- 2003-11-19 RS YU20050376A patent/RS51606B/sr unknown
- 2003-11-19 SI SI200331205T patent/SI1562613T1/sl unknown
- 2003-11-19 PL PL377022A patent/PL214006B1/pl unknown
- 2003-11-19 US US10/535,330 patent/US7255813B2/en not_active Expired - Lifetime
- 2003-11-19 CN CNA2003801035544A patent/CN1713916A/zh active Pending
-
2005
- 2005-06-10 NO NO20052839A patent/NO333911B1/no not_active IP Right Cessation
- 2005-06-17 HR HRP20050573AA patent/HRP20050573B1/hr not_active IP Right Cessation
-
2011
- 2011-02-25 JP JP2011039874A patent/JP2011144186A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS614798A (ja) * | 1984-06-19 | 1986-01-10 | 東亞合成株式会社 | 高度不飽和脂肪酸組成物 |
JPH05503071A (ja) * | 1989-08-18 | 1993-05-27 | ジョン・モリス・カンパニー・インク | ケラチン組織、皮膚状態を治療し、創傷の治癒を促進させる臭気遮断及び安定化組成物 |
JPH08512021A (ja) * | 1993-04-29 | 1996-12-17 | バークメイヤー ユー.エス.エー. | 安定性、摂取可能及び吸収性のnadh及びnadph治療組成物 |
JPH08231404A (ja) * | 1995-01-17 | 1996-09-10 | Birkmayer Usa | 経鼻、経舌下、経直腸及び経皮投与のためのnadh及びnadph治療剤 |
JP2001061498A (ja) * | 1999-08-31 | 2001-03-13 | Oriental Yeast Co Ltd | 還元型補酵素溶液 |
EP1161884A1 (en) * | 2000-06-09 | 2001-12-12 | World Pharma Tech Ltd. | Proenergetic food supplement based on NADH, Octacosanol and Vitamin E |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011144186A (ja) * | 2002-11-19 | 2011-07-28 | Nutropia Ernaehrungsmedizinische Forschungs Gmbh | Nadh/nadphを含む組成物 |
JP2012161293A (ja) * | 2011-02-08 | 2012-08-30 | Shin Nihon Iyaku Corp | 酸化誘導性が向上した緑茶抽出液及びこれを含有してなる食品、飲料、洗浄剤及び抗菌剤 |
JP2015040204A (ja) * | 2013-08-23 | 2015-03-02 | 京都府公立大学法人 | 運動機能性向上剤 |
Also Published As
Publication number | Publication date |
---|---|
PL377022A1 (pl) | 2006-01-23 |
AT502435A1 (de) | 2007-03-15 |
CN1713916A (zh) | 2005-12-28 |
PL214006B1 (pl) | 2013-06-28 |
HRP20050573B1 (hr) | 2013-10-11 |
ES2302957T3 (es) | 2008-08-01 |
NO333911B1 (no) | 2013-10-21 |
NO20052839L (no) | 2005-06-10 |
EP1562613B1 (de) | 2008-03-12 |
PT1562613E (pt) | 2008-06-06 |
US20060011891A1 (en) | 2006-01-19 |
WO2004045626A1 (de) | 2004-06-03 |
RU2005119190A (ru) | 2005-11-20 |
EP1562613A1 (de) | 2005-08-17 |
RS20050376A (en) | 2007-12-31 |
RU2338540C2 (ru) | 2008-11-20 |
JP2011144186A (ja) | 2011-07-28 |
CA2503860C (en) | 2011-09-13 |
AT502435B1 (de) | 2008-01-15 |
SI1562613T1 (sl) | 2008-08-31 |
DK1562613T3 (da) | 2008-07-14 |
ATE388714T1 (de) | 2008-03-15 |
RS51606B (sr) | 2011-08-31 |
AU2003287740A1 (en) | 2004-06-15 |
HRP20050573A2 (en) | 2006-07-31 |
DE50309383D1 (de) | 2008-04-24 |
CA2503860A1 (en) | 2004-06-03 |
US7255813B2 (en) | 2007-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011144186A (ja) | Nadh/nadphを含む組成物 | |
Dai et al. | T-2 toxin neurotoxicity: role of oxidative stress and mitochondrial dysfunction | |
US9623042B2 (en) | Combination preparation for improving sperm quality | |
US20030206972A1 (en) | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect | |
US20050267212A1 (en) | Omega-3 fatty acids in the treatment of depression | |
TWI245628B (en) | Stabilized composition of reduced coenzyme Q10 aqueous solution | |
JP2007526303A (ja) | 可溶化coq−10およびカルニチン | |
Sun et al. | Mitochondrial nutrients stimulate performance and mitochondrial biogenesis in exhaustively exercised rats | |
Sepe et al. | Oxidant membrane injury by the neutrophil myeloperoxidase system. II. Injury by stimulated neutrophils and protection by lipid-soluble antioxidants. | |
ES2308550T3 (es) | Formulacion para administracion oral que ejerce un efecto reconstituyente sobre el sistema cardiovascular. | |
KR20140136915A (ko) | 세포손상 효과에 대한 보호를 제공하는 조성물 | |
US20190240281A1 (en) | Oral anaerobic glutathione supplement in liposome suspension | |
Aramli et al. | Effect of dietary antioxidant supplements (selenium forms, alpha-tocopherol, and coenzyme Q10) on growth performance, immunity, and physiological responses in rainbow trout (Oncorhynchus mykiss) using orthogonal array design | |
CN114901083A (zh) | 含有芝麻素类及pqq的组合物 | |
Grune et al. | Low molecular weight antioxidants | |
US20020120001A1 (en) | Compositions containing tryptamines, cartenoids and tocotrienols and having synergistic antioxidant effect | |
EP1870095A1 (en) | Composition for increasing anti-oxidation activity in blood | |
US20200338153A1 (en) | Anaerobic antioxidant composition | |
HU227182B1 (en) | Lecitin-ascorbic acid combination | |
Celik et al. | Influence of dietary selenium and vitamin E on the levels of fatty acids in brain and liver tissues of lambs | |
Zulaikhah et al. | The impact of tender coconut water on preventing lipid peroxidation and increasing antioxidant enzymes in lead-induced rats | |
Kadir et al. | CoEnzyme Q10: A new horizon in the treatment of periodontal diseases. | |
CA3041914C (en) | Anaerobic antioxidant composition | |
JP2020183351A (ja) | 嫌気性抗酸化組成物 | |
RU2468791C2 (ru) | Композиция, обладающая адаптогенным, общеукрепляющим и повышающим работоспособность действием |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100217 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100513 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100817 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110502 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110510 |